JP2019512535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512535A5 JP2019512535A5 JP2018551351A JP2018551351A JP2019512535A5 JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5 JP 2018551351 A JP2018551351 A JP 2018551351A JP 2018551351 A JP2018551351 A JP 2018551351A JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- compound
- alkyl
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163571.9 | 2016-04-01 | ||
| EP16163571 | 2016-04-01 | ||
| PCT/EP2017/057765 WO2017167993A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512535A JP2019512535A (ja) | 2019-05-16 |
| JP2019512535A5 true JP2019512535A5 (OSRAM) | 2020-04-23 |
| JP6968092B2 JP6968092B2 (ja) | 2021-11-17 |
Family
ID=55650321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551351A Active JP6968092B2 (ja) | 2016-04-01 | 2017-03-31 | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10669286B2 (OSRAM) |
| EP (1) | EP3436459B1 (OSRAM) |
| JP (1) | JP6968092B2 (OSRAM) |
| CN (1) | CN109195969B (OSRAM) |
| BR (1) | BR112018069936A2 (OSRAM) |
| CA (1) | CA3019026A1 (OSRAM) |
| EA (1) | EA201892153A1 (OSRAM) |
| WO (1) | WO2017167993A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| SG10201911831RA (en) | 2015-08-03 | 2020-02-27 | Bristol Myers Squibb Co | Heterocyclic compounds useful as modulators of tnf alpha |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN108948034B (zh) * | 2018-06-05 | 2019-09-13 | 河南大学 | 一种色满桥环异吲哚酮及其制备方法 |
| ES2951837T3 (es) * | 2018-10-24 | 2023-10-25 | UCB Biopharma SRL | Derivados de imidazol pentacíclicos condensados como moduladores de la actividad de TNF |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| TW202513567A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商上海翰森生物醫藥科技有限公司 | 五環類衍生物抑制劑、其製備方法與應用 |
| WO2025038927A1 (en) * | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
| WO2025212627A1 (en) * | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025218735A1 (zh) * | 2024-04-17 | 2025-10-23 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603926A1 (en) | 2003-03-10 | 2005-12-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| KR101941420B1 (ko) | 2011-06-20 | 2019-01-23 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 억제제의 인산에스테르 |
| TR201807207T4 (tr) * | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| US9309243B2 (en) | 2012-07-13 | 2016-04-12 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EP3201196B1 (en) * | 2014-10-03 | 2021-07-28 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives |
-
2017
- 2017-03-31 CA CA3019026A patent/CA3019026A1/en not_active Abandoned
- 2017-03-31 EA EA201892153A patent/EA201892153A1/ru unknown
- 2017-03-31 CN CN201780033199.XA patent/CN109195969B/zh not_active Expired - Fee Related
- 2017-03-31 WO PCT/EP2017/057765 patent/WO2017167993A1/en not_active Ceased
- 2017-03-31 EP EP17714783.2A patent/EP3436459B1/en active Active
- 2017-03-31 US US16/086,418 patent/US10669286B2/en active Active
- 2017-03-31 JP JP2018551351A patent/JP6968092B2/ja active Active
- 2017-03-31 BR BR112018069936A patent/BR112018069936A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512535A5 (OSRAM) | ||
| JP2019512533A5 (OSRAM) | ||
| JP2014513139A5 (OSRAM) | ||
| JP2017531648A5 (OSRAM) | ||
| JP2016040288A5 (OSRAM) | ||
| JP2014513110A5 (OSRAM) | ||
| JP2016520618A5 (OSRAM) | ||
| JP2014139226A5 (OSRAM) | ||
| JP2016525075A5 (OSRAM) | ||
| JP2014525420A5 (OSRAM) | ||
| JP2015143283A5 (OSRAM) | ||
| JP2018501315A5 (OSRAM) | ||
| JP2014513140A5 (OSRAM) | ||
| ME02203B (me) | Hinolin i hinoksalin derivati kao inhibitori kinaza | |
| JP2013529611A5 (OSRAM) | ||
| JP2012525431A5 (OSRAM) | ||
| JP2016525076A5 (OSRAM) | ||
| JP2016523270A5 (OSRAM) | ||
| JP2016522232A5 (OSRAM) | ||
| JP2016515582A5 (OSRAM) | ||
| HRP20201094T1 (hr) | IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA | |
| JP2013540712A5 (OSRAM) | ||
| RU2013136542A (ru) | Конденсированные производные аминодигидротиазина | |
| JP2014510147A5 (OSRAM) | ||
| JP2017517538A5 (OSRAM) |